Mohit Bansal: Maybe one question, if I can ask. So regarding the expenses for COVID business, Dave, you mentioned that you will be essentially relaunching these products with the commercial scale and everything. So is there — so how much cost, given that your COVID business is declining significantly this year? Are you modeling any kind of cost cuts in that business or should more — or dollar basis are still the same? And is there any synergies you can achieve, especially for vaccine with your existing Prevnar business because the channels are similar or not? And last part is, do you think you can do more share buybacks, given the stock price at this point? Thank you.
Dr. Albert Bourla: Let me take the first two quickly. Of course, as you saw, the business is going down because of COVID, the average is growing. Expenses are going up because we are promoting new launches, including COVID. So right now, moving into Comirnaty in commercial and Paxlovid with commercial channels, now we treat them like normal promotional products, very sensitive in promotions at the beginning of their launch. So, we are going very hard with promotions, TV, field forces and all the other educational measures that we are taking when we do this type of launch. So there is — clearly this speaks. What about, David, are we going to buy back?
Dave Denton: I think as we look at capital allocation at this point in time, we actually see a lot of opportunities to invest back into our business, both from a research perspective and importantly, getting behind our launches to make sure that we’re doing all that we can to ensure that our growth trajectory in €˜25 and €˜30 and those goals and aspirations become reality. So, I think our best and highest use of capital right now is investing in our business, both internally as well as from a BD perspective. I would say never say never to an incremental share repurchase, but that’s not high on the priority list at this point.
Dr. Albert Bourla: And Mohit also, you asked also about the synergies. Clearly, there are a lot of synergies right now both. In the Paxlovid — Paxlovid is covered by a lot of physicians, and we have very, very strong primary care field force and we have very strong also vaccines field force that is covering all these physicians that we have, either vaccinate or prescribing Paxlovid. So, clearly, a lot of synergies in retail and in the medical profession also. Let’s go to the next call, please.
Operator: From Chris Schott with JPMorgan.
Chris Schott: Just building on some of the OpEx discussion here. I just want to make sure I’m understanding the OpEx dynamic is properly over time. So, I guess, should we think about 2023 as more of a onetime step-up in OpEx and then much slower growth in €˜24 and beyond? Or should we be thinking about this a couple of year process as you really get the pipeline and new products ramped, and then it’s maybe more second half of the decade before we think even about margin — bigger margin expansion or is that OpEx slowing? I just want to make sure I’m understanding those dynamics properly. And then the second one was on the COVID/flu combination. I guess, is your expectation that the tolerability of that will be similar to what we see with Comirnaty, or is there some trade-off of we could see maybe slightly higher kind of side effects for the six components you mentioned but that’s offset by the convenience?
I’m just trying to make sure I understand what your expectations are for that program. Thanks so much.
Dr. Albert Bourla: Thank you very much, Chris. To this scientific question to Mikael, first.
